We’re delighted to announce the shortlist for the Citeline Biotech Awards 2026. Celebrating our tenth anniversary, these awards honor excellence at the forefront of biotech research, development, and clinical innovation. Recognized as one of the industry’s leading global programs, they celebrate the biotech organizations, teams, and individuals advancing science, driving clinical trial excellence, and shaping the future of healthcare.
This year, we introduced new categories designed to reflect the dynamism of the biotech sector, spotlighting outstanding achievement in oncology, neuroscience, rare disease drug development, patient-first approaches, and transformative technology innovation. They sit alongside recognition of partnerships, clinical research teams, breakthrough trial results, and the most coveted accolade of the evening, BioPharma Company of the Year. Together, the categories capture the speed, scientific conviction, and patient focus that define the biotech model.
We congratulate everyone who made the shortlist. Winners will be revealed at the awards ceremony in Boston on Thursday, November 12, 2026.
View the 2026 shortlist to see this year’s finalists.
Click here to see our full entry guide for more information on the categories and criteria.
Thursday, 12 November 2026
Doors open at 6pm · Ceremony & gala dinner
InterContinental Boston
510 Atlantic Ave, Boston, MA 02210
10 Categories
“This Award will recognise the efforts of an individual, team, or company that demonstrated excellence while developing a drug intended to treat rare diseases.”
The attempt to combat rare diseases is a challenging task that exemplifies how the pharmaceutical industry addresses unmet medical needs. This Award will recognise the efforts of an individual, team, or company that demonstrated excellence while developing a drug intended to treat rare diseases. The judges will be looking for a drug development programme or trial with the largest potential impact in the rare disease space. Outstanding patient-centric processes and innovation in study conduct to overcome the various obstacles of rare disease drug development will also earn high marks.
FINALISTS
“Biotech companies are redefining the future of cancer treatment combining cutting-edge science with an unwavering focus on patients who need new options most. This Award celebrates those leading that charge.”
Cancer drug development has been transformed by the biotech sector. From pioneering immuno-oncology approaches to precision medicine and novel targeted therapies, biotech companies have consistently pushed the boundaries of what is scientifically and clinically possible in oncology. Operating with speed, scientific conviction, and a willingness to tackle the hardest problems, biotech organisations have become the engine of oncology innovation bringing first-in-class and best-in-class therapies to patients who have long faced limited options. This Award will recognize a biotech company that has demonstrated outstanding achievement in the research, development, or clinical execution of an oncology program, and whose work reflects the very best of what the biotech model can deliver.
FINALISTS
“Biotech companies are redefining what is possible in neuroscience bringing bold science and relentless focus to conditions that have long resisted progress. This Award celebrates those at the frontier of that effort.”
Neurological and psychiatric conditions represent some of the most scientifically complex and historically underserved areas of medicine. Biotech companies have increasingly become the driving force behind bold, first-in-class approaches to these devastating diseases bringing scientific creativity, agility, and patient focus to an area where large-scale drug development has historically struggled to deliver. This Award will recognize a biotech company that has demonstrated outstanding achievement in the research, development, or clinical execution of a neuroscience program. The judges will be looking for a company that has leveraged the unique strengths of the biotech model speed, innovation, and scientific conviction to meaningfully advance the standard of care or address a significant unmet medical need in neurology or psychiatry.
FINALISTS
“The judges will be looking to reward the high-performing team that has been most successful in reaching its goals, adopted effective working practices, achieved major milestones within expected timelines, and contributed to the advancement of new therapies.”
The winning biotech research team will have made significant contributions in advancing a new therapy through one or more clinical phases. The judges will be looking to reward the high-performing team that has been most successful in reaching its goals, adopted effective working practices, achieved major milestones within expected timelines, and contributed to the advancement of new therapies.
FINALISTS
“This Award will be presented to two or more organizations who have set a new benchmark in partnering through collaborative clinical trial activity that took place in 2025/26.”
This Award will be presented to two or more organisations who have set a new benchmark in partnering through collaborative clinical trial activity that took place in 2025/26. Partnerships for this award must be between a pharmaceutical or biotech company and a contract research organisation.
FINALISTS
“This Award will recognize a technology solution that has moved beyond promise and into proven impact transforming the way clinical research is conducted and setting a new benchmark for innovation across the industry.”
Technology is fundamentally reshaping the way clinical research is designed, conducted, and delivered. From artificial intelligence and machine learning to decentralised trial platforms, digital biomarkers, and advanced data analytics, the application of innovative technology across the drug development continuum is accelerating timelines, improving data quality, reducing patient burden, and unlocking insights that were previously out of reach. This Award will recognize a company or team that has developed or applied a technology-driven solution that has made a measurable and demonstrable impact on clinical research or drug development. The judges will be looking for innovations that go beyond incremental improvement solutions that are genuinely transformative, scalable, and represent a meaningful step forward for the industry.
FINALISTS
“This Award celebrates those who have made a genuine and lasting commitment to ensuring that the patient voice is not just heard but acted upon placing the people at the heart of clinical research firmly at the centre of every decision.”
At the heart of every clinical trial, every drug development program, and every regulatory milestone is a patient. The most meaningful advances in clinical research are not measured solely in data points and endpoints they are measured in the lives changed, the burdens reduced, and the voices heard. Across the biopharmaceutical industry, a growing number of organisations are embedding patient centricity not as a principle, but as a practice fundamentally redesigning how trials are conceived, conducted, and communicated with the patient experience at the centre. This Award will recognize a company, team, or individual that has demonstrated an exceptional and authentic commitment to putting patients first going beyond compliance and convention to ensure that the needs, preferences, and perspectives of patients genuinely shape the way clinical research is designed and delivered.
The judges will be looking for entries that demonstrate real, measurable impact on the patient experience not simply good intentions or standard practice. Evidence of meaningful collaboration with patients and patient advocacy groups, innovative approaches to reducing patient burden, and a demonstrable shift in how the organisation thinks and operates will all be highly valued.
FINALISTS
“This Award will recognise the clinical trial which reported results that had the greatest impact and is expected to lead to an advance in healthcare.”
The judges will be looking to reward the clinical trial with the largest commercial impact, highest impact on patient population, the greatest disruption in a market, or the advancement of clinical trial design. This might include the first demonstration of a clear clinical effect for a new drug in an area of unmet medical need, a pivotal study of a new drug with a breakthrough mechanism of action, or a major study of a potential new or expanded indication for an already marketed product.
FINALISTS
“With this award, we are looking to recognise the accomplishments of an exceptional individual with a consistent history of significant contributions to the biotech research and development field.”
This award will go to someone who has had a distinguished career in R&D or clinical research, working at a biotech company. The nominee should have a history of successful projects that have had a positive impact on human health. Metrics can include scientific publications and citations; patents and involvement in innovation; involvement in clinical trials and drug approvals; and contributions to the development of future scientists and leaders in the field through mentorship, training programmes, and leadership roles in professional organisations.
“The Bio Pharma Company of the Year Award is the most coveted recognition of the evening celebrating an organisation that has excelled across every dimension of what it means to be a leader in biopharmaceutical research and development, and whose work during the qualifying period has made a genuine and lasting contribution to the advancement of human health.”
The biopharmaceutical industry demands extraordinary things from the organisations that operate within it. Scientific excellence, clinical execution, commercial acumen, and an unwavering commitment to patients must all be sustained simultaneously often in the face of significant uncertainty, resource constraints, and the relentless pressure of an industry where the stakes could not be higher. This Award will recognize the biopharmaceutical or biotech company that has demonstrated the most outstanding overall performance across the clinical research and drug development landscape during the qualifying period. This is the most prestigious award of the evening a recognition not of a single achievement, but of an organisation that has excelled across multiple dimensions and demonstrated what it truly means to be a leader in this industry.
The judges will be looking for a company that has made a measurable and meaningful impact across a broad range of activities from scientific innovation and clinical execution to patient engagement, partnerships, and organisational culture. A compelling Company of the Year entry will tell a coherent story of an organisation firing on all cylinders, whose collective achievements during the qualifying period set it apart from its peers and reflect a clear and authentic commitment to advancing human health.
FINALISTS
ICON plc is a world-leading clinical research organisation. Offering deep operational and medical expertise we accelerate innovation, driving emerging therapies forward to improve patient outcomes. From molecule to medicine, we deliver integrated consulting, clinical development, commercialisation and post-marketing solutions to pharmaceutical, biotechnology, medical device, government and public health organisations worldwide. With headquarters in Dublin, Ireland, ICON employed approximately 40,200 employees in 99 locations in 55 countries as of June 30, 2026.
For further information about ICON, visit: https://www.iconplc.com/biotech.
Jane Bentley
VP Oncology Therapeutic Strategy and Innovation
View profile
VP Oncology Therapeutic Strategy and Innovation
Insitute of Clinical Research
Jane holds a BSc in Pharmacology and a PhD in Toxicology from University of London.
She is currently a member of the board at the Institute of Clinical Research and previously held the post of Hon Lecturer in Clinical Research at Liverpool John Moores University. She has over 35 years Oncology drug development experience in the pharmaceutical industry including Executive Leadership, project and portfolio management in Oncology and hematology drug development and has been with Syneos Health since May 2016. Her current role is to drive strategic innovation in oncology for clients and internal teams, partnering with customers to bring a solutions-based approach to drug development.
Jane is an active leader in Syneos Health’s cross functional innovation initiatives for the Patient Voice, Cell and Gene Therapy and Rare Disease.
Jeffrey M. Bockman, PhD
EVP, Head of the Oncology Center of Excellence
View profile
EVP, Head of the Oncology Center of Excellence
Lumanity
Jeff leads the Oncology Practice at Lumanity (previously Cello Health BioConsulting, previously Defined Health). Jeff has extensive commercial and strategic perspective on the pharmaceutical and biotech industries. He often speaks at conferences on scientific and strategic issues in cancer, especially immuno-oncology.
Jeff leads the Oncology Practice at Lumanity (previously Cello Health BioConsulting, previously Defined Health). Jeff has extensive commercial and strategic perspective on the pharmaceutical and biotech industries. He often speaks at conferences on scientific and strategic issues in cancer, especially immuno-oncology.
Before joining Cello Health BioConsulting/Defined Health, Jeff was a Senior Research Scientist and Research Project Leader in the commercial development of oligonucleotide therapeutics for viral diseases and cancer at Innovir Laboratories; and an Assistant Research Professor at The George Washington University School of Medicine. He has worked closely with two Nobel Prize recipients: Dr. Sidney Altman on ribozymes, and Dr. Stanley Prusiner on prions, and holds four patents in the use of ribozymes.
He received a BA from University of California at San Diego, a PhD in Medical Microbiology from the University of California at Berkeley, and an MA in English/Creative Writing from New York University. Jeff is a member of the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), the American Society of Gene and Cell Therapy (ASGCT), the Society for Immunotherapy of Cancer (SITC) and the New York Academy of Sciences (NYAS).
Jeff is a mentor for the NCI Innovation Conference, a member of the Evaluation Committee for the NCI SBIR Phase IIB Bridge Award Program, a judge for the Citeline Awards, a member of the Advisory "Group" to Skipper Bio Med (a preclinical research consultancy that provides pro bono services to academic and industry groups, developing promising lung and/or pancreatic cancer therapeutics/device. Skipper is fully supported by a private US family that has been personally impacted by these cancers and is committed to bridging the research “valley of death”).
Jeff is a member of the Clinical Advisory Board of ImmunOS (an immunotherapy company based in Zurich), the Advisory Board of Pearl Therapeutics (a synthetic biology company based in Cambridge, MA), and a Strategic Advisor to Alloplex (a cell therapy platform company based in Cambridge, MA). He has previously been a member of the Scientific Advisory Board of hC Bioscience (a novel RNA-based platform company in Cambridge, MA), and Valo Therapeutics (an oncolytic virus and vaccine company based in Helsinki, Finland).
George Gasparis
President
View profile
President
The PEER Consulting Group
George Gasparis has over 35 years of experience in the administration or conduct of human subjects research. Prior to founding “PEER”, he served as the Asst. VP and Sr. Asst. Dean for Research Ethics at Columbia University (CU), CU Medical Center (CUMC) from 2003-12, where he directed the IRB Office and compliance team.
He worked at the Office for Human Research Protections (OHRP) for seven years and served as the Director, Division of Assurances and Quality Improvement from 2000-03, where he led the development of the OHRP QI Program and electronic submission of the Federalwide Assurance (FWA). He has also served as the Director, The George Washington University Medical Center (GWUMC) IRB and Research Pharmacy after serving as a Data Manager for over 40 clinical trials at GWUMC.
Ross Pettit, MBA
Chief Development Officer
View profile
Chief Development Officer
Kestrel Therapeutics
Ross is the Chief Development Officer at Kestrel Therapeutics, where he leads day-to-day operations and drives strategic execution across functions to ensure operational excellence and business alignment. With more than 35 years of experience in drug development and biotech operations, he has a strong track record of building high-performing teams and bringing innovative therapies to market. His expertise spans multiple therapeutic areas, with a focus on cross-functional leadership, alliance management, and global development strategy. Ross has held senior leadership roles at companies including Charm Therapeutics, H3 Biomedicine, Otsuka, EMD Serono, Coley, ARIAD, Infinity, and BeiGene. His international experience covers the Americas, Europe, and Asia. He holds an M.B.A. in Healthcare Management from the University of Phoenix and a B.Sc. (Hons) from Kingston University, London.
Ross is the Chief Development Officer at Kestrel Therapeutics, where he leads day-to-day operations and drives strategic execution across functions to ensure operational excellence and business alignment. With more than 35 years of experience in drug development and biotech operations, he has a strong track record of building high-performing teams and bringing innovative therapies to market. His expertise spans multiple therapeutic areas, with a focus on cross-functional leadership, alliance management, and global development strategy. Ross has held senior leadership roles at companies including Charm Therapeutics, H3 Biomedicine, Otsuka, EMD Serono, Coley, ARIAD, Infinity, and BeiGene. His international experience covers the Americas, Europe, and Asia. He holds an M.B.A. in Healthcare Management from the University of Phoenix and a B.Sc. (Hons) from Kingston University, London.
Michael Rice
Senior Vice President
View profile
Senior Vice President
Lumanity's Cell and Gene Therapy
Mike is Senior Vice President of Lumanity's Cell and Gene Therapy pratice, specializing in strategic development of platform technologies and applications for genetically defined patient populations and broad polygenic diseases. He also co-leads the hematologic oncology and cardiometabolics practices.
He has 25+ years of experience in biotech ventures supporting new company creation and defining strategic development and early commercial strategy for academic and biotech inventions pertaining to nucleic acids, gene therapy and cellular platforms applied across monogenetic diseases and oncology. Mike studied the molecular basis of cancer at the Kimmel Cancer Institute and is recognized for his extensive intellectual property and publication portfolio pertaining to recombinational DNA repair and molecular diagnostics. Mike is a co-inventor of non-nuclease gene editing methodology currently used commercially in agricultural trait improvement and in development for therapeutic applications.
Mike holds an MBA, with a concentration in Biotechnology from the Alfred Lerner School of Business and Economics, at the University of Delaware, an MS in Molecular Pharmacology from Thomas Jefferson University and a Bachelor of Science degree in Biology from the University of Delaware. Industry positions involved translational research, strategic planning, technology transfer, finance and business development.
Mike is a Member of the Pennsylvania Biotechnology Center Advisory Council, enjoys mentoring early-stage life science entrepreneurs and is a member of ASGCT, ARM, SITC, ASCO and AHA professional societies.
Marissa Volpe
Clinical Development Operations Executive
View profile
Clinical Development Operations Executive
Marissa Volpe is a clinical development operations executive with nearly 30 years of experience across biotechnology, pharmaceutical, and CRO organizations. Most recently, she served as Senior Vice President and Head of Clinical Development Operations at Stoke Therapeutics, leading global development operations for rare disease programs. Marissa is recognized for her expertise in clinical trial execution, CRO and vendor oversight, operational strategy, and building high-performing teams. A highly connected industry leader, she is passionate about advancing Development Operations as a strategic driver of successful drug development and bringing innovative therapies to patients.
Marissa Volpe is a clinical development operations executive with nearly 30 years of experience across biotechnology, pharmaceutical, and CRO organizations. Most recently, she served as Senior Vice President and Head of Clinical Development Operations at Stoke Therapeutics, leading global development operations for rare disease programs. Marissa is recognized for her expertise in clinical trial execution, CRO and vendor oversight, operational strategy, and building high-performing teams. A highly connected industry leader, she is passionate about advancing Development Operations as a strategic driver of successful drug development and bringing innovative therapies to patients.
Mike Ward
Award-Winning Writer, Editor, Commentator and Thought Leadership Leader
View profile
Award-Winning Writer, Editor, Commentator and Thought Leadership Leader
Mike Ward is a highly regarded, award-winning writer, editor, commentator and thought leadership leader with more than four decades of experience covering the global life sciences and healthcare industries. Throughout his career, he has held senior editorial and content leadership positions at several of the industry's most influential organisations, including BioCentury, Informa and Clarivate.
Widely recognised for his ability to translate complex scientific, commercial and policy developments into compelling business intelligence, Mike has written extensively on drug discovery, clinical development, healthcare innovation, regulatory change and pharmaceutical strategy. He is a sought-after moderator, interviewer and speaker, having led discussions with industry executives, scientists, investors and policymakers across the global life sciences ecosystem.
Over the course of his career, Mike has built a reputation as one of the sector's most respected voices, combining deep industry knowledge with a talent for identifying emerging trends and helping organisations understand their strategic implications. His work has informed senior decision-makers across the pharmaceutical, biotechnology, investment and healthcare communities.
